Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + XELOX + Bevacizumab in MSS mCRC with High Immune Infiltrate
NCT04262687Phase 2Unknown
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Apr 2021
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colorectal cancer (metastatic) (mCRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-Free Survival at 10 months. Status: unknown.
02
Drugs
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04262687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262687.